SPL7013 shows significant activity against SARS-CoV-2 (coronavirus)

Following the outbreak of coronavirus earlier this year, Starpharma instigated laboratory testing of Starpharma’s antiviral dendrimer, SPL7013. In April, the Company reported that SPL7013 has demonstrated significant activity against SARS-CoV-2 (coronavirus), which causes COVID-19.

SPL7013 is the active component in Starpharma’s range of marketed VivaGel® products (VivaGel® BV and the VivaGel® condom), which are already sold in Australia/NZ, UK, Europe, Canada, Japan and South East Asia. Given that products containing SPL7013 are already approved in the above markets, the existing preclinical and clinical data on file creates the opportunity to fast-track the development and commercialisation of SPL7013-based product(s) for COVID-19.

Starpharma is now exploring a number of product opportunities, including a potential preventative application to prevent/reduce the risk of infection. Such a product could provide additional personal protection including for those in the frontline of this crisis, such as doctors, nurses and other essential workers, and is in keeping with Starpharma’s strategy to expand commercial applications of its dendrimers.

Download ASX Announcement: SPL7013 shows significant activity against SARS-CoV-2 (coronavirus) (pdf file, 69kb)


COVID-19 measures

Like most organisations around the world, Starpharma continues to closely monitor the COVID-19 pandemic and its impact.

The health and safety of our people, trial patients and VivaGel® customers is paramount. Starpharma has implemented a broad program of measures to protect the health and safety of staff and clinical trial patients, and to ensure product supply to customers.

The Company has established a range of strategies and controls to mitigate the impact of COVID-19 on its business and continues to update these as the situation evolves. Starpharma’s business operations continue to operate with minimal disruption, with stringent hygiene protocols in place to ensure that staff can continue in their roles in a safe and secure way, including work from home arrangements, virtual meetings, minimal onsite visitation and frequent cleaning/disinfecting on the premises.

The Company’s laboratory and in-house GMP manufacturing facilities are currently in full operation, and collaborations with various groups continue, which enables preclinical programs, other research and clinical trial support to progress as normal.

Further information regarding COVID-19 was provided in the Company’s Quarterly Cashflow & Activity Report.

We will continue to update our policies based on medical advice and changes to Government directives and encourage staff to do what they can to prevent the spread.

Our management team is monitoring and reviewing the situation daily, and we will continue to update our measures as appropriate.